Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CSU Clear all

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 (blinded), Placebo, LOU064 (open label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab, Omalizumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 34
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Oral EP262, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more

Conditions: Chronic Idiopathic Urticaria
Interventions: AZD1981, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Chronic Idiopathic Urticaria
Interventions: Xolair; Biological
Lead sponsor: Asthma Inc Clinical Research Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Spontaneous Urticaria
Interventions: LY3454738, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 18
States / cities: Bakersfield, California • Fountain Valley, California • Lancaster, California + 13 more

Conditions: Lung Cancer
Interventions: Centralized Screening Unit Implementation; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 50 Years to 77 Years
Enrollment: 9,460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Chronic Spontaneous Urticaria
Interventions: EVO756, Placebo control; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more

Conditions: Chronic Spontaneous Urticaria
Interventions: AK006 IV; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,033 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 39
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Conditions: Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 40
States / cities: Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab, Omalizumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 30
States / cities: Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more

Conditions: Rhinitis, Urticaria
Interventions: levocetirizine or placebo; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Interventions: AK006-IV, Placebo-IV, AK006-SC, Placebo-SC; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 7 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more

Conditions: Chronic Urticaria
Interventions: Omalizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Urticaria
Interventions: GDC-0853; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more

Search by objective public record fields.

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria

A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

Centralized Screening Unit (CSU) at Montefiore-Einstein

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Remibrutinib in Real-world Clinical Practice - a US Sub-study

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study